Cyclosporine Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy

C. Edward Dixon, Helen Bramlett, W. Dalton Dietrich, Deborah A. Shear, Hong Q. Yan, Ying Deng-Bryant, Stefania Mondello, Kevin K W Wang, Ronald L. Hayes, Philip E. Empey, John T. Povlishock, Frank C. Tortella, Patrick M. Kochanek

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Operation Brain Trauma Therapy (OBTT) is a consortium of investigators using multiple pre-clinical models of traumatic brain injury (TBI) to bring acute therapies to clinical trials. To screen therapies, we used three rat models (parasagittal fluid percussion injury [FPI], controlled cortical impact [CCI], and penetrating ballistic-like brain injury [PBBI]). We report results of the third therapy (cyclosporin-A; cyclosporine; [CsA]) tested by OBTT. At each site, rats were randomized to treatment with an identical regimen (TBI + vehicle, TBI + CsA [10 mg/kg], or TBI + CsA [20 mg/kg] given intravenously at 15 min and 24 h after injury, and sham). We assessed motor and Morris water maze (MWM) tasks over 3 weeks after TBI and lesion volume and hemispheric tissue loss at 21 days. In FPI, CsA (10 mg/kg) produced histological protection, but 20 mg/kg worsened working memory. In CCI, CsA (20 mg/kg) impaired MWM performance; surprisingly, neither dose showed benefit on any outcome. After PBBI, neither dose produced benefit on any outcome, and mortality was increased (20 mg/kg) partly caused by the solvent vehicle. In OBTT, CsA produced complex effects with histological protection at the lowest dose in the least severe model (FPI), but only deleterious effects as model severity increased (CCI and PBBI). Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No positive treatment effects were seen on biomarker levels in any of the models, whereas significant increases in 24 h UCH-L1 levels were seen with CsA (20 mg/kg) after CCI and 24 h GFAP levels in both CsA treated groups in the PBBI model. Lack of behavioral protection in any model, indicators of toxicity, and a narrow therapeutic index reduce enthusiasm for clinical translation.

Original languageEnglish (US)
Pages (from-to)553-566
Number of pages14
JournalJournal of Neurotrauma
Volume33
Issue number6
DOIs
StatePublished - Mar 15 2016

Fingerprint

Cyclosporine
Percussion
Brain Injuries
Ubiquitin Thiolesterase
Wounds and Injuries
Glial Fibrillary Acidic Protein
Therapeutics
Biomarkers
Traumatic Brain Injury
Water
Protein C
Short-Term Memory
Research Personnel
Clinical Trials
Mortality

Keywords

  • biomarker
  • calcineurin
  • controlled cortical impact
  • fluid percussion
  • neuroprotection
  • penetrating ballistic-like brain injury
  • phosphatase
  • rat
  • therapy

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Cyclosporine Treatment in Traumatic Brain Injury : Operation Brain Trauma Therapy. / Dixon, C. Edward; Bramlett, Helen; Dalton Dietrich, W.; Shear, Deborah A.; Yan, Hong Q.; Deng-Bryant, Ying; Mondello, Stefania; Wang, Kevin K W; Hayes, Ronald L.; Empey, Philip E.; Povlishock, John T.; Tortella, Frank C.; Kochanek, Patrick M.

In: Journal of Neurotrauma, Vol. 33, No. 6, 15.03.2016, p. 553-566.

Research output: Contribution to journalArticle

Dixon, CE, Bramlett, H, Dalton Dietrich, W, Shear, DA, Yan, HQ, Deng-Bryant, Y, Mondello, S, Wang, KKW, Hayes, RL, Empey, PE, Povlishock, JT, Tortella, FC & Kochanek, PM 2016, 'Cyclosporine Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy', Journal of Neurotrauma, vol. 33, no. 6, pp. 553-566. https://doi.org/10.1089/neu.2015.4122
Dixon, C. Edward ; Bramlett, Helen ; Dalton Dietrich, W. ; Shear, Deborah A. ; Yan, Hong Q. ; Deng-Bryant, Ying ; Mondello, Stefania ; Wang, Kevin K W ; Hayes, Ronald L. ; Empey, Philip E. ; Povlishock, John T. ; Tortella, Frank C. ; Kochanek, Patrick M. / Cyclosporine Treatment in Traumatic Brain Injury : Operation Brain Trauma Therapy. In: Journal of Neurotrauma. 2016 ; Vol. 33, No. 6. pp. 553-566.
@article{0237044fa8424d1790dbf883d0950c8a,
title = "Cyclosporine Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy",
abstract = "Operation Brain Trauma Therapy (OBTT) is a consortium of investigators using multiple pre-clinical models of traumatic brain injury (TBI) to bring acute therapies to clinical trials. To screen therapies, we used three rat models (parasagittal fluid percussion injury [FPI], controlled cortical impact [CCI], and penetrating ballistic-like brain injury [PBBI]). We report results of the third therapy (cyclosporin-A; cyclosporine; [CsA]) tested by OBTT. At each site, rats were randomized to treatment with an identical regimen (TBI + vehicle, TBI + CsA [10 mg/kg], or TBI + CsA [20 mg/kg] given intravenously at 15 min and 24 h after injury, and sham). We assessed motor and Morris water maze (MWM) tasks over 3 weeks after TBI and lesion volume and hemispheric tissue loss at 21 days. In FPI, CsA (10 mg/kg) produced histological protection, but 20 mg/kg worsened working memory. In CCI, CsA (20 mg/kg) impaired MWM performance; surprisingly, neither dose showed benefit on any outcome. After PBBI, neither dose produced benefit on any outcome, and mortality was increased (20 mg/kg) partly caused by the solvent vehicle. In OBTT, CsA produced complex effects with histological protection at the lowest dose in the least severe model (FPI), but only deleterious effects as model severity increased (CCI and PBBI). Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No positive treatment effects were seen on biomarker levels in any of the models, whereas significant increases in 24 h UCH-L1 levels were seen with CsA (20 mg/kg) after CCI and 24 h GFAP levels in both CsA treated groups in the PBBI model. Lack of behavioral protection in any model, indicators of toxicity, and a narrow therapeutic index reduce enthusiasm for clinical translation.",
keywords = "biomarker, calcineurin, controlled cortical impact, fluid percussion, neuroprotection, penetrating ballistic-like brain injury, phosphatase, rat, therapy",
author = "Dixon, {C. Edward} and Helen Bramlett and {Dalton Dietrich}, W. and Shear, {Deborah A.} and Yan, {Hong Q.} and Ying Deng-Bryant and Stefania Mondello and Wang, {Kevin K W} and Hayes, {Ronald L.} and Empey, {Philip E.} and Povlishock, {John T.} and Tortella, {Frank C.} and Kochanek, {Patrick M.}",
year = "2016",
month = "3",
day = "15",
doi = "10.1089/neu.2015.4122",
language = "English (US)",
volume = "33",
pages = "553--566",
journal = "Journal of Neurotrauma",
issn = "0897-7151",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Cyclosporine Treatment in Traumatic Brain Injury

T2 - Operation Brain Trauma Therapy

AU - Dixon, C. Edward

AU - Bramlett, Helen

AU - Dalton Dietrich, W.

AU - Shear, Deborah A.

AU - Yan, Hong Q.

AU - Deng-Bryant, Ying

AU - Mondello, Stefania

AU - Wang, Kevin K W

AU - Hayes, Ronald L.

AU - Empey, Philip E.

AU - Povlishock, John T.

AU - Tortella, Frank C.

AU - Kochanek, Patrick M.

PY - 2016/3/15

Y1 - 2016/3/15

N2 - Operation Brain Trauma Therapy (OBTT) is a consortium of investigators using multiple pre-clinical models of traumatic brain injury (TBI) to bring acute therapies to clinical trials. To screen therapies, we used three rat models (parasagittal fluid percussion injury [FPI], controlled cortical impact [CCI], and penetrating ballistic-like brain injury [PBBI]). We report results of the third therapy (cyclosporin-A; cyclosporine; [CsA]) tested by OBTT. At each site, rats were randomized to treatment with an identical regimen (TBI + vehicle, TBI + CsA [10 mg/kg], or TBI + CsA [20 mg/kg] given intravenously at 15 min and 24 h after injury, and sham). We assessed motor and Morris water maze (MWM) tasks over 3 weeks after TBI and lesion volume and hemispheric tissue loss at 21 days. In FPI, CsA (10 mg/kg) produced histological protection, but 20 mg/kg worsened working memory. In CCI, CsA (20 mg/kg) impaired MWM performance; surprisingly, neither dose showed benefit on any outcome. After PBBI, neither dose produced benefit on any outcome, and mortality was increased (20 mg/kg) partly caused by the solvent vehicle. In OBTT, CsA produced complex effects with histological protection at the lowest dose in the least severe model (FPI), but only deleterious effects as model severity increased (CCI and PBBI). Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No positive treatment effects were seen on biomarker levels in any of the models, whereas significant increases in 24 h UCH-L1 levels were seen with CsA (20 mg/kg) after CCI and 24 h GFAP levels in both CsA treated groups in the PBBI model. Lack of behavioral protection in any model, indicators of toxicity, and a narrow therapeutic index reduce enthusiasm for clinical translation.

AB - Operation Brain Trauma Therapy (OBTT) is a consortium of investigators using multiple pre-clinical models of traumatic brain injury (TBI) to bring acute therapies to clinical trials. To screen therapies, we used three rat models (parasagittal fluid percussion injury [FPI], controlled cortical impact [CCI], and penetrating ballistic-like brain injury [PBBI]). We report results of the third therapy (cyclosporin-A; cyclosporine; [CsA]) tested by OBTT. At each site, rats were randomized to treatment with an identical regimen (TBI + vehicle, TBI + CsA [10 mg/kg], or TBI + CsA [20 mg/kg] given intravenously at 15 min and 24 h after injury, and sham). We assessed motor and Morris water maze (MWM) tasks over 3 weeks after TBI and lesion volume and hemispheric tissue loss at 21 days. In FPI, CsA (10 mg/kg) produced histological protection, but 20 mg/kg worsened working memory. In CCI, CsA (20 mg/kg) impaired MWM performance; surprisingly, neither dose showed benefit on any outcome. After PBBI, neither dose produced benefit on any outcome, and mortality was increased (20 mg/kg) partly caused by the solvent vehicle. In OBTT, CsA produced complex effects with histological protection at the lowest dose in the least severe model (FPI), but only deleterious effects as model severity increased (CCI and PBBI). Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No positive treatment effects were seen on biomarker levels in any of the models, whereas significant increases in 24 h UCH-L1 levels were seen with CsA (20 mg/kg) after CCI and 24 h GFAP levels in both CsA treated groups in the PBBI model. Lack of behavioral protection in any model, indicators of toxicity, and a narrow therapeutic index reduce enthusiasm for clinical translation.

KW - biomarker

KW - calcineurin

KW - controlled cortical impact

KW - fluid percussion

KW - neuroprotection

KW - penetrating ballistic-like brain injury

KW - phosphatase

KW - rat

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=84962224160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962224160&partnerID=8YFLogxK

U2 - 10.1089/neu.2015.4122

DO - 10.1089/neu.2015.4122

M3 - Article

C2 - 26671075

AN - SCOPUS:84962224160

VL - 33

SP - 553

EP - 566

JO - Journal of Neurotrauma

JF - Journal of Neurotrauma

SN - 0897-7151

IS - 6

ER -